Just days after a capital-markets day left investors wondering what’s next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。
Veytics Intelligence
After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring
